SYNGR1

Across TCGA pan-cancer cohorts, SYNGR1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SYNGR1 data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SYNGR1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYNGR1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where SYNGR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.880	0.614	.009	20	view →
HNSC	OS	Quartile	II,III,IV	0.924	0.721	.013	10	view →
PDAC	DFS	Median	All	0.305	0.522	.016	10	view →
UCEC	OS	Median	II,III,IV	0.675	1.000	.023	4	view →
GBM	OS	Quartile	All	0.238	0.636	.023	4	view →
LSCC	DFS	Median	II,III,IV	0.692	0.856	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SYNGR1–LUAD (OS)

Open the LUAD breakdown →